
































































Effectiveness of Systematic Echocardiographic Screening
for Rheumatic Heart Disease in Nepalese Schoolchildren
A Cluster Randomized Clinical Trial
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IMPORTANCE Echocardiographic screening allows for early detection of subclinical stages of
rheumatic heart disease among children in endemic regions.
OBJECTIVE To investigate the effectiveness of systematic echocardiographic screening in
combination with secondary antibiotic prophylaxis on the prevalence of rheumatic heart
disease.
DESIGN, SETTING, AND PARTICIPANTS This cluster randomized clinical trial included students 9
to 16 years of age attending public and private schools in urban and rural areas of the Sunsari
district in Nepal that had been randomly selected on November 17, 2012. Echocardiographic
follow-up was performed between January 7, 2016, and January 3, 2019.
INTERVENTIONS In the experimental group, children underwent systematic
echocardiographic screening followed by secondary antibiotic prophylaxis in case they had
echocardiographic evidence of latent rheumatic heart disease. In the control group, children
underwent no echocardiographic screening.
MAIN OUTCOMES AND MEASURES Prevalence of the composite of definite or borderline
rheumatic heart disease according to the World Heart Federation criteria in experimental and
control schools as assessed 4 years after intervention.
RESULTS A total of 35 schools were randomized to the experimental group (n = 19) or the
control group (n = 16). After a median of 4.3 years (interquartile range [IQR], 4.0-4.5 years),
17 of 19 schools in the experimental group (2648 children; median age at follow-up, 12.1 years;
IQR, 10.3-12.5 years; 1308 [49.4%] male) and 15 of 16 schools in the control group (1325
children; median age at follow-up, 10.6 years; IQR, 10.0-12.5 years; 682 [51.5%] male)
underwent echocardiographic follow-up. The prevalence of definite or borderline rheumatic
heart disease was 10.8 per 1000 children (95% CI, 4.7-24.7) in the control group and 3.8 per
1000 children (95% CI, 1.5-9.8) in the experimental group (odds ratio, 0.34; 95% CI, 0.11-1.07;
P = .06). The prevalence in the experimental group at baseline had been 12.9 per 1000
children (95% CI, 9.2-18.1). In the experimental group, the odds ratio of definite or borderline
rheumatic heart disease at follow-up vs baseline was 0.29 (95% CI, 0.13-0.65; P = .008).
CONCLUSIONS AND RELEVANCE School-based echocardiographic screening in combination
with secondary antibiotic prophylaxis in children with evidence of latent rheumatic heart
disease may be an effective strategy to reduce the prevalence of definite or borderline
rheumatic heart disease in endemic regions.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT01550068
JAMA Cardiol. 2021;6(4):420-426. doi:10.1001/jamacardio.2020.7050
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R heumatic heart disease (RHD) is acquired during child-hood and causes more than 10 million disability-adjusted life-years every year, accounting for most
deaths from valvular heart disease worldwide.1,2 The burden
of RHD is disproportionately prevalent in marginalized com-
munities across sub-Saharan Africa, South Asia, and the Pa-
cific Islands, where endemic patterns of disease prevail.1,3 Strat-
egies to target RHD include secondary antibiotic prophylaxis
in children with a history of acute rheumatic fever. Second-
ary antibiotic prophylaxis is recommended by the World Health
Organization4 and has been associated with a reduced risk of
recurrence of acute rheumatic fever and death.5 The effective-
ness of secondary prophylaxis is, however, limited by the of-
ten oligosymptomatic course of rheumatic fever, resulting in
a substantial burden of latent RHD among children and ado-
lescents in regions with an endemic pattern of disease.6 Echo-
cardiographic screening has been advocated as a strategy to
allow for the early detection of latent RHD.7 A previous cross-
sectional study8 using echocardiographic screening for RHD
in Nepal found that 10 per 1000 children had evidence of RHD,
with 4 of 5 cases being latent. Early detection of subclinical
stages of RHD and timely initiation of secondary antibiotic pro-
phylaxis for latent disease may reverse subclinical valvular le-
sions, prevent disease progression, and contain the reservoir
for further spread.9 There is, however, no randomized evi-
dence available to support this notion. Herein we describe the
results of a cluster randomized trial to investigate the effec-
tiveness of systematic echocardiographic screening for latent
RHD followed by secondary antibiotic prophylaxis in chil-
dren with echocardiographic evidence of valvular disease in
reducing the prevalence of RHD in adolescents.
Methods
Setting and Design
In December 2012, we launched a school-based echocardio-
graphic screening program in an evaluable random sample of
schools in the Sunsari district of Nepal, which was planned in
collaboration with the district education office.8 The Sunsari
district is situated on the foothills of the lower Himalayan range
in the eastern development region of Nepal and is part of the
Outer Terai of the Koshi zone. As 1 of 75 districts in Nepal, the
Sunsari district extends over an area comparable in size to New
York City and has a total population of more than 760 000
inhabitants. The sampling frame comprised the total of 595 pri-
mary and secondary schools in the Sunsari district registered
in 2012. Central random sampling of schools, stratified by set-
ting (rural vs urban) and administration of the school (public
vs private), was performed on November 17, 2012. Within each
stratum, all schools were ordered according to a computer-
generated random sequence,10 with eligibility of schools de-
termined according to the random sequence. Rural to urban
schools were selected in a 3:1 ratio and public to private schools
in a 2:1 ratio to reflect the distribution of all children in the edu-
cational system in Nepal.11 The trial protocol can be found in
Supplement 1. Written informed consent was obtained from
school principals of all included schools. Data were not dei-
dentified. The study was approved by the institutional re-
view board of B.P. Koirala Institute of Health Sciences and the
Nepal Health Research Council. This study followed the Con-
solidated Standards of Reporting Trials (CONSORT) reporting
guideline.
The study was initially conceived as a prospective, single-
group, interventional study of the effect of echocardio-
graphic screening followed by antibiotic treatment (if medi-
cally indicated) on the prevalence of RHD in a locally
representative random sample of schools.8 However, in Au-
gust 2013, a random sample of control schools was addition-
ally selected at the request of the Nepal Health Research Coun-
cil based on the random sequence generated in November 2012.
This random control sample was selected before completion
of recruitment of schools and children for the experimental
group of the study and more than 2 years before initiation of
follow-up in January 2016. The sampling approach allowed for
a cluster randomized comparison of experimental and con-
trol schools at follow-up. Children were eligible for the ran-
domized cluster comparison if their age at baseline was be-
tween 5 and 12 years. Schools with at least 10 children in this
age range were eligible. All children in the eligible age range
were approached to undergo on-site echocardiographic ex-
amination at baseline8 and follow-up in experimental schools
and at follow-up only in control schools. Children and their par-
ents or primary caregivers were given the opportunity to opt
out. The project was accompanied by a public awareness cam-
paign in local news media.
Procedures
Echocardiographic follow-up examinations were performed by
2 trained physicians (K.S. and S.D.), who were blinded to study
group allocation and who were unaware of the findings of pre-
vious examinations performed in the experimental schools,
using a battery-powered portable ultrasound machine (My-
SonoU6; Samsung Medison). Children with morphologic fea-
tures or pathological valvular function suggestive of RHD un-
derwent confirmatory examination at the B.P. Koirala Institute
Key Points
Question Is echocardiographic screening of schoolchildren in
regions with an endemic pattern of rheumatic heart disease
followed by secondary antibiotic prophylaxis in children with
evidence of subclinical rheumatic heart disease effective in
reducing the prevalence of rheumatic heart disease?
Findings This cluster randomized clinical trial found a
nonstatistically significant lower prevalence of definite or
borderline rheumatic heart disease in schools with
echocardiographic screening 4 years after intervention compared
with control schools with no previous screening. An auxiliary
repeated cross-sectional analysis of experimental schools found a
significant reduction in the odds of definite or borderline
rheumatic heart disease.
Meaning A lower prevalence of rheumatic heart disease in
schools with prior echocardiographic screening warrants further
study of the effectiveness of early detection and timely treatment
of rheumatic heart disease in children and adolescents.
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of Health Sciences in Dharan, Nepal. Physicians (N.P. and P.S.)
performing confirmatory echocardiography were blinded to
whether children attended experimental or control schools.
Children with definite or borderline RHD were included in a
prospective registry and recommended annual clinical and
echocardiographic follow-up. All children with definite RHD
at any time point throughout the study were recommended
to receive secondary antibiotic prophylaxis with intramuscu-
lar benzathine benzylpenicillin (600 000 IU for those weigh-
ing <30 kg and 1 200 000 IU for those weighing ≥30 kg) once
a month. Children with borderline RHD were not adminis-
tered a secondary antibiotic prophylaxis. All administrations
of the medication were delivered by trained study personnel.
Children were considered adherent if they had received at least
2 doses of intramuscular benzathine benzylpenicillin or an al-
ternative antibiotic in the 3 months before follow-up. Details
of data collection and data management are summarized in the
eMethods in Supplement 2.
Study Outcomes
The primary outcome was the prevalence of definite or bor-
derline RHD defined according to the World Heart Federation
criteria for individuals 20 years or younger in schools en-
rolled into the experimental vs control group at follow-up.12
Definite RHD was defined by at least 2 of 4 morphologic fea-
tures and pathological valvular regurgitation or stenosis or bor-
derline disease of both the aortic and the mitral valve. Bor-
derline RHD was defined by at least 2 morphologic features of
the valvular apparatus or the presence of pathological valvu-
lar regurgitation.12 Secondary outcomes of the within-group
comparison in the experimental group included regression
from definite to borderline RHD and remission of valvular pa-
thology. In children in the experimental group who received
secondary antibiotic prophylaxis, the following safety end
points were prospectively recorded: death, cerebrovascular
events, hospitalizations for heart failure, and allergic reac-
tions to penicillin.
Statistical Analysis
Assuming an intraclass correlation coefficient of 0.001,13 we
estimated that 34 schools with a mean of 100 children 9 to 16
years of age randomized in a 1:1 ratio would yield 87% power
to detect a reduction in the primary outcome from 12 per 1000
children in the control group8 to 2 per 1000 children in the ex-
perimental group, 77% power to detect a reduction from 12 to
3 per 1000 children, and 64% power to detect a reduction from
12 to 4 per 1000 children after a planned follow-up of approxi-
mately 3 years at a 2-sided α = .05. The sample size calcula-
tion was not adjusted for unavailability of follow-up. To com-
pare the marginal odds of the composite of definite or
borderline RHD between the experimental and control schools,
we used a random-effects, multilevel logistic regression model,
including setting (rural vs urban) and school administration
(public vs private) as covariates at school level and age at base-
line and sex as covariates at children level. In addition, we used
a random intercept to account for clustering within schools.
Marginal estimates were derived with respect to the median
proportions of rural and public schools, the median propor-
tion of girls, and the median of the arithmetic mean of the age
of children at follow-up across all schools of the cluster ran-
domized comparison that were followed up. To derive preva-
lence estimates with 95% CIs, we transformed odds and cor-
responding boundaries of 95% CIs to probabilities. All children
who underwent follow-up were included in the analysis ac-
cording to their school’s randomization. Prespecified sub-
group analyses were performed according to age at baseline
(5 to ≤8 years vs >8 to 12 years), sex, and school administra-
tion (public vs private) and were accompanied by a test for in-
teraction from the random-effects multilevel model. The sub-
group analysis according to setting (rural vs urban) did not
converge. To compare the marginal odds of the composite of
definite or borderline RHD between baseline and follow-up in
a repeated cross-sectional study of experimental schools, we
also included a nested random intercept in the multilevel lo-
gistic regression model to account for clustering within chil-
dren. Echocardiographic outcomes of children in experimen-
tal schools with definite RHD at the screening examination at
baseline were explored using spaghetti plots, and the percent-
age of children with regression to borderline disease or remis-
sion was compared in children with less than 2.5 years of maxi-
mal follow-up and children with 2.5 years or more of maximal
follow-up using a 2-sided Fisher exact test. Projections for the
expansion of the screening program to the entire district are
detailed in the eMethods in Supplement 2. All analyses were
conducted in Stata software, version 15 (StataCorp LLC). All P
values and 95% CIs are 2-sided. P < .05 was considered to be
statistically significant.
Results
Thirty-five schools were included in the study and random-
ized to the experimental group (n = 19) or the control group
(n = 16) (Figure 1). Between December 12, 2012, and August 22,
2014, all eligible children 5 to 12 years of age from the 19 schools
in the experimental group underwent echocardiographic
screening at baseline, whereas no screening was performed in
the 16 schools in the control group. Between January 7, 2016,
and January 3, 2019, after a median interval of 4.3 years (in-
terquartile range [IQR], 4.0-4.5 years), children aged 9 to 16
years at 17 experimental and 15 control schools underwent fol-
low-up; 2 experimental schools were unavailable for fol-
low-up because of a logistical error, and 1 control school had
been closed after randomization. All 2648 eligible children
(1308 [49.4%] male) attending the 17 experimental schools and
all 1325 eligible children (682 [51.5%] male) attending the 15
control schools underwent echocardiographic ascertainment
of the prespecified primary outcome. Demographic charac-
teristics, which are summarized in the Table, were well bal-
anced between experimental and the control schools, with ex-
ception of the median number of students per school, which
was 77 (IQR, 46-249) in the experimental group and 49 (IQR,
28-101) in the control group. Six of 17 schools (35.3%) in the
experimental group and 5 of 15 schools (33.3%) in the control
group were private schools. The median of the arithmetic mean
age of children per school at follow-up was 12.1 years (IQR, 10.3-
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12.5 years) in the experimental group and 10.6 years (IQR, 10.0-
12.5 years) in the control group. The timeline of outcome as-
certainment at follow-up in experimental and control schools
is illustrated in eFigure 1 in Supplement 2.
Randomized Cluster Comparison
At follow-up, 13 of 2648 children in experimental schools had
definite (n = 2) or borderline (n = 11) RHD, and 17 of 1325 chil-
dren in control schools had definite (n = 2) or borderline (n = 15)
RHD.TheestimatedprevalenceofdefiniteorborderlineRHDwas
3.8 per 1000 children (95% CI, 1.5-9.8) in the experimental group
and 10.8 per 1000 children (95% CI, 4.7-24.7) in the control group
(odds ratio [OR], 0.34; 95% CI, 0.11-1.07; P = .06) (Figure 2). In-
tracluster correlation was 0.24 (95% CI, 0.07-0.56). In a sensi-
tivity analysis that included only cases of definite RHD, the ef-
fect of echocardiographic screening and secondary prophylaxis
in children with latent RHD was consistent with the primary end
point analysis (OR, 0.49; 95%, CI 0.07-3.60; P = .49). In pre-
specifiedsubgroupanalyses,nosignificantinteractionwasfound
between the effect of echocardiographic screening and rural or
urban setting, public or private administration of schools, age
at baseline, or sex of children (Figure 3). In experimental schools,
definite disease in 2 children and borderline disease in 9 chil-
dren were newly detected cases, whereas 2 children with bor-
derline disease at follow-up had been diagnosed with definite
disease at the screening examination. Nine children in experi-
mental schools who were diagnosed with definite (n = 5) or bor-
derline disease (n = 4) at the screening examination did not have
signs of RHD at follow-up. The remaining 19 children in the eli-
gible range in experimental schools who were diagnosed with
definite (n = 16) or borderline disease (n = 3) at the screening ex-
amination no longer attended experimental schools at
follow-up.
Auxiliary Repeated Cross-sectional Analysis
of Experimental Schools
At the screening examination, 50 of 4181 examined children
in experimental schools were diagnosed with borderline or defi-
nite RHD, with an estimated prevalence of 9.7 per 1000 (95%
CI, 6.9-13.6). Among the 2940 children 9 years or older, 42 chil-
dren were diagnosed with definite or borderline RHD, with an
estimated prevalence of 12.9 per 1000 children (95% CI, 9.2-
18.1). At the time of follow-up, 13 of 2648 children in the same
age range from the same schools had definite or borderline
RHD, with an estimated prevalence of 3.8 per 1000 children
(95% CI, 1.5-9.8). In a comparison across time, the OR for defi-
nite or borderline RHD between follow-up and baseline ex-
amination was 0.29 (95% CI, 0.13-0.65; P = .008) (Figure 2).
Follow-up of Children in Experimental Schools
With Definite RHD at Screening Examination
At the screening examination, 23 children 5 to 12 years of age,
who were eligible for the randomized cluster comparison, had
definite RHD and were prescribed secondary prophylaxis with
penicillin. Seven children could be definitively linked at fol-
low-up at a median of 4.3 years after the screening examina-
tion (range, 3.9-4.6 years), with 5 children in remission and
Figure 1. Study Flowchart According to the CONSORT Statement
595 Registered schools in the Sunsari district
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follow-up because it 
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(n = 1325 students)




2 Schools unavailable for
follow-up because of 
logistical errors
Table. Demographic Characteristics of the Study Schools and Children
Characteristic
Experimental group
(n = 17 schools and
2648 children)
Control group (n = 15
schools and 1325
children)
Type of school, No. (%)
Urban area 4 (23.5) 3 (20.0)
Private 6 (35.3) 5 (33.3)
No. of children per school,
median of the mean (IQR)
77 (46-249) 49 (28-101)
Age per school at baseline,
median of the
mean (IQR), y
8.2 (6.3-9.0) 7.5 (6.0-8.3)
Age per school at
follow-up,
median of the qamean
(IQR), y
12.1 (10.3-12.5) 10.6 (10.0-12.5)
Boys per school,
No. (%) [IQR]
33 (48.9) [41.9-55.0] 23 (51.3) [42.6-56.0]
Abbreviation: IQR, interquartile range.
Figure 2. Prevalence of Definite and Borderline Rheumatic Heart Disease

























Error bars indicate 95% CIs.
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2 children with regression to borderline disease. Sixteen chil-
dren could not be definitively linked. Of these, 13 children had
undergone additional routine echocardiographic examina-
tions at a median follow-up of 1.2 years (range, 0.9-4.7 years),
with 1 child having regression to borderline disease and 12 con-
tinuing to have echocardiographic signs of definite RHD. The
remaining 3 children were unavailable for follow-up. Among
the 20 children who had at least 1 follow-up, 15 (75.0%) had
received at least 2 antibiotic doses in the 3 months before fol-
low-up and were considered adherent. Figure 4 details the 20
children with any echocardiographic follow-up. Among 15 chil-
dren with a maximum follow-up less than 2.5 years after the
screening examination, regression or remission was docu-
mented in 4 (26.7%); among 10 children with maximum fol-
low-up of 2.5 years or more, regression or remission was docu-
mented in 7 (70.0%) (P = .049). All children with regression
or remission of disease had been adherent to secondary pro-
phylaxis. eFigure 2 in Supplement 2 details the 9 children with
definite RHD in the ineligible age range of 13 to 15 years at the
screening examination who had undergone echocardio-
graphic follow-up at a median of 1 year (range, 0.8-4.7 years):
2 children had a regression to borderline disease, and 7 chil-
dren continued to have echocardiographic signs of definite
RHD. Another 2 children with definite RHD in the ineligible age
range were unavailable for follow-up. None of the children in
the experimental group who began secondary prophylaxis ex-
perienced an allergic reaction to penicillin or any other safety
end point.
Projections for Studied District
We estimated that approximately 220 000 children 5 to 16 years
of age lived in the Sunsari district in 2016.11 A 10-year strategy
of 3 teams examining approximately 50 000 children annu-
ally during the first 3 years and 32 000 children annually dur-
ing years 4 to 10 in a school-based screening program cover-
ing the entire district would allow the examination of 19 birth
cohorts, including approximately 300 000 children at least
once, with approximately 80 000 children receiving 2 exami-
nations at an interval of 6 years. We estimated that this ap-
proach would result in the detection of 2900 children with bor-
derline or definite RHD (95% CI, 2100-4100). The projected cost
of the strategy during 10 years would be $1.4 million (eTable
in Supplement 2), which corresponds to a mean of $4.67 per
child examined or $483 per detected RHD case (95% CI,
$341-$667).
Discussion
In this cluster randomized clinical trial of 35 Nepalese schools,
with follow-up of 32 schools with 3973 children, a lower preva-
lence of definite or borderline RHD in schools with echocar-
diographic screening 4 years prior compared with control
schools with no previous screening did not reach conven-
tional levels of statistical significance (odds ratio, 0.34; 95%
CI, 0.11-1.07; P = .06). In an auxiliary repeated cross-
sectional analysis of experimental schools, we found a signifi-
cant reduction in the odds of definite or borderline RHD. The
magnitudes of the reductions observed in the cluster random-
ized comparison and the auxiliary repeated cross-sectional
analysis were similar. A 71% decrease in RHD prevalence be-
tween baseline and follow-up after implementation of an in-
tervention with biologically plausible efficacy is corrobo-
rated by individual patient trajectories. In addition, the
prevalence of RHD in the control group at follow-up was com-














































All subgroup analyses were post hoc.
Odds ratios (ORs) (95% CIs) are
estimated using the Mantel-Cox
method with 2-sided P values from
the log-rank test. P values for
interactions were obtained with
approximate χ2 tests for unequal ORs
in the subgroups.
Figure 4. Longitudinal Data of Children in the Experimental Group










Orange lines indicate children in the eligible age range who underwent
follow-up in the setting of the auxiliary cross-sectional examination; blue lines,
children in the eligible age range who no longer attended (the same) school.
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parable to the prevalence in the experimental group at the
screening examination. The consistency of these observa-
tions suggests that a strategy of echocardiographic screening
and treatment of latent RHD may be effective in preventing dis-
ease progression, reversing subclinical valvular lesions, and
containing the infectious reservoir. The projections made for
the studied Sunsari district highlight the burden of RHD among
Nepalese schoolchildren and suggest that a school-based, 10-
year, systematic screening program could be implemented in
the district at the modest cost of US $1.4 million.
Subclinical valvular lesions of RHD that are detected early
are reversible.14 School-based systematic echocardiographic
screening represents a pragmatic approach to detect children
with early-stage disease in low-resource settings, with initia-
tion of secondary antibiotic prophylaxis before valvular patholo-
gies become irreversible. Focused cardiac ultrasonography by
nonexperts has been associated with acceptable sensitivity and
specificity for the detection of RHD and may facilitate imple-
mentation of population-based screening programs in en-
demicregions.15 Whenanalyzingthefollow-updataofthe10chil-
dren in experimental schools with definite RHD at the screening
examination with a follow-up of 2.5 years or more, we found 7
children with a documented regression or remission. Among the
15 children with a shorter follow-up, only 4 had a documented
regression or remission. Small prospective cohort studies found
2 of 8 children (25%) with definite RHD in Uganda14 and 5 of 11
children (45%) with definite RHD in Malawi16 with a regression
or remission after approximate follow-up durations of 2 years.
The randomized GwokO Adunu pa Lutino (GOAL) trial, which
is currently recruiting to achieve a target sample size of 916 chil-
dren, was designed to determine the effect of secondary peni-
cillin prophylaxis on the course of latent RHD.17 The primary out-
come of the trial will be ascertained after 2 years of follow-up.
Our exploratory results suggest that the effectiveness of peni-
cillin could increase with even longer follow-up.
Early implementation of secondary antibiotic prophy-
laxis represents a pragmatic approach to the silent epidemic
of RHD. A comprehensive program that combines primary and
secondary prevention with health education, community in-
volvement, and epidemiologic surveillance resulted in an ef-
fective reduction of the burden of RHD in Cuba.18 Awareness
and research funding for RHD disproportionally trails the en-
gagement and expenditure for other diseases, such as tuber-
culosis and malaria, and is dwarfed by the resources spent on
degenerative valvular heart disease.19
Limitations
This study has several limitations. First, this was a cluster ran-
domized clinical trial performed in a resource-constrained set-
ting that was complicated by administrative challenges, 2 ma-
jor earthquakes, and civil unrest regarding a new constitution,
during which schools were closed for 4 months.20-22 These fac-
tors resulted in 2 experimental schools being unavailable for
follow-up because of logistical errors and 1 control school being
unavailable for follow-up because it remained closed after the
civil unrest. Second, the mean follow-up of this trial was more
than 1 year longer than originally planned as a direct conse-
quence of the earthquakes and civil unrest. Third, resource con-
straints meant that we were only able to randomize 35 schools,
with follow-up of 32 schools. In addition, the size of the schools
in the control group was smaller than anticipated. Taken to-
gether, these factors meant that the power of our trial to de-
tect a clinically meaningful reduction in definite or border-
line RHD was limited. Fourth, our results cannot be generalized
to children who dropped out of school early because our fol-
low-up was restricted to children who attended school be-
tween the ages of 9 to 16 years. This limitation is important be-
cause the percentage of children out of school is considerable
in Nepal and may have increased after the earthquakes and civil
unrest.11,23 Fifth, the auxiliary repeated cross-sectional study
of experimental schools was complicated by a lower-than-
expected success rate in linking data between screening ex-
amination and follow-up because of errors in children-
reported Nepalese names and dates of birth, variations in
Western translations of names, and clustering of children-
reported dates of birth. The 95% CI of the OR of the auxiliary
repeated cross-sectional study is therefore conservative and
would have been more narrow if a higher percentage of chil-
dren had been linked in the absence of errors, variation, and
clustering of identifying information. Sixth, we did not as-
sess intrarater and interrater variability for the detection of RHD
in the current study. Seventh, as per our protocol, we used ad-
herence to antibiotic prophylaxis within the past 3 months as
an approximation of adherence with antibiotic prophylaxis
throughout the study period and did not use standard tools,
such as records from health care professionals or patient
diaries.
Conclusion
We found evidence, albeit statistically nonsignificant, that
school-based echocardiographic screening in combination with
secondary antibiotic prophylaxis in children with evidence of
latent RHD reduces the prevalence of definite or borderline
RHD in endemic regions. A lower prevalence of RHD in schools
with prior echocardiographic screening compared with con-
trol schools and a significant reduction in the prevalence of
RHD in experimental schools between baseline and fol-
low-up warrant further study of the effectiveness of early
detection and timely treatment of RHD in children and
adolescents.
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